After a discussion on the HPV vaccine with a mother and her 10-year-old daughter at a well-child visit, the nurse recognizes the discussion was successful when the mother makes which statement?

A. Avoid or reduce painful procedures: Atraumatic care focuses on minimizing or eliminating pain whenever possible through comfort measures, distraction techniques, and appropriate pain management. This helps decrease fear and anxiety in children during medical procedures.

B. Avoid or reduce physical distress: Preventing physical stress such as discomfort, fatigue, or temperature extremes supports the child’s sense of safety and comfort. This approach helps reduce physiological and emotional trauma during hospitalization.

C. Minimize parent-child interactions: This is contrary to atraumatic care principles. Parental presence provides comfort and emotional security for the child. Family-centered involvement enhances coping and promotes healing.

D. Provide child-centered care: Atraumatic care emphasizes care that respects the child’s developmental level, preferences, and emotional needs. This individualized approach promotes trust, reduces anxiety, and fosters cooperation.

E. Minimize child control: Atraumatic care encourages giving the child as much control as appropriate, such as allowing choices when possible. Limiting control increases fear and feelings of helplessness.

F. Use core primary nursing: Consistent caregivers foster a sense of security and continuity, reducing stress and promoting therapeutic relationships. This supports the child’s emotional well-being and stability during hospitalization.

A. DNA ploidy status: This test analyzes the number and structure of chromosomes within tumor cells to determine malignancy aggressiveness. It is used after cancer is diagnosed, not for assessing hereditary risk in an asymptomatic person.

B. Digital mammography: Mammography is a screening tool for detecting existing breast abnormalities or early cancer, not a genetic risk assessment. It is recommended for routine screening, typically starting at age 40 or earlier if the woman is at high risk.

C. BRCA-1 genetic marker: Testing for BRCA-1 (and BRCA-2) mutations identifies women with a hereditary predisposition to breast and ovarian cancer. A positive result indicates a significantly higher lifetime risk and guides preventive and surveillance strategies.

D. Fine-needle biopsy: This diagnostic procedure is used to evaluate an existing breast lump or suspicious lesion for malignancy. It does not identify genetic or hereditary cancer risk in asymptomatic individuals.